SOUTH SAN FRANCISCO, Calif.--AxyS Pharmaceuticals here last month received US patents on two proprietary genes, TULP 1 and TULP 2, that have been linked to two disease states. The disease linkages and details of some of the properties of TULP 1 are being published in the current issue of Nature Genetics, according to John Walker, AxyS's chairman and CEO. He declined further comment on the patents pending publication of the article.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.